Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ACB 
Aurora Cannabis Inc (ACB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: ACB (1-star) is a SELL. SELL since 2 days. Profits (-3.51%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -43.61% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 229.83M USD | Price to earnings Ratio 18.55 | 1Y Target Price 32.07 |
Price to earnings Ratio 18.55 | 1Y Target Price 32.07 | ||
Volume (30-day avg) 1206474 | Beta 3.32 | 52 Weeks Range 3.42 - 7.20 | Updated Date 06/22/2025 |
52 Weeks Range 3.42 - 7.20 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.66% | Operating Margin (TTM) -32.88% |
Management Effectiveness
Return on Assets (TTM) 0.62% | Return on Equity (TTM) 2.6% |
Valuation
Trailing PE 18.55 | Forward PE 18.83 | Enterprise Value 236963664 | Price to Sales(TTM) 0.72 |
Enterprise Value 236963664 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 0.92 | Enterprise Value to EBITDA 6.18 | Shares Outstanding 56246400 | Shares Floating 56000859 |
Shares Outstanding 56246400 | Shares Floating 56000859 | ||
Percent Insiders - | Percent Institutions 19.7 |
Analyst Ratings
Rating 4.17 | Target Price 32.07 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aurora Cannabis Inc
Company Overview
History and Background
Aurora Cannabis Inc. was founded in 2006 in Canada. Initially focused on medical cannabis, it expanded rapidly through acquisitions and strategic partnerships, aiming to become a global leader in the cannabis industry. It experienced significant growth followed by restructuring due to market fluctuations.
Core Business Areas
- Cannabis Production and Sales: Cultivating and selling cannabis products, including dried flower, oils, concentrates, vapes, and edibles, for both medical and recreational markets.
- Medical Cannabis: Focuses on producing and distributing medical cannabis products to patients and healthcare providers globally.
- Consumer Cannabis: Aurora sells recreational cannabis products to consumers in Canada.
- International Cannabis: Exports medical cannabis to various countries with legal cannabis markets.
Leadership and Structure
The leadership team includes Miguel Martin (CEO). The organizational structure comprises various departments responsible for cultivation, production, research, sales, marketing, and finance. The Board of Directors oversees the company's strategic direction.
Top Products and Market Share
Key Offerings
- Dried Flower: Aurora offers a wide range of dried cannabis flower products with varying potency and strains. Aurora's cannabis flower market share is estimated to be around 3%. Competitors are Canopy Growth, Tilray, and Organigram. Revenue data is not publicly available per product, but part of total cannabis revenue
- Cannabis Oils: Aurora produces cannabis oils for various applications, including tinctures and capsules. Market share is estimated to be around 4%. Competitors are Canopy Growth, Tilray, and Organigram. Revenue data is not publicly available per product, but part of total cannabis revenue
- Vapes: Aurora also sells vape products. Market share is estimated to be around 2%. Competitors are Canopy Growth, Tilray, and Organigram. Revenue data is not publicly available per product, but part of total cannabis revenue
Market Dynamics
Industry Overview
The cannabis industry is growing but highly competitive and subject to evolving regulations. It is influenced by changing consumer preferences, scientific advancements, and regulatory approvals worldwide.
Positioning
Aurora Cannabis Inc. aims to be a premium cannabis producer, focusing on quality and innovation. They are positioned to leverage medical cannabis opportunities and the recreational market in Canada. They are working towards improving market share.
Total Addressable Market (TAM)
The global cannabis market is projected to reach hundreds of billions of dollars in the next few years. Aurora is aiming to capture a significant portion of this market through strategic expansions and product innovation. However, competition is intense, requiring continuous adaptation and cost management.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in the cannabis sector
- Advanced cultivation and production facilities
- Focus on medical cannabis market
- International presence and partnerships
Weaknesses
- History of net losses
- High operating expenses
- Significant debt load
- Dilution of shareholder value through equity offerings
Opportunities
- Expansion into new international markets
- Development of innovative cannabis products
- Increasing acceptance and legalization of cannabis globally
- Partnerships with pharmaceutical companies for medical applications
Threats
- Intense competition from other cannabis companies
- Fluctuations in cannabis prices
- Strict regulations and compliance requirements
- Changing consumer preferences and market trends
Competitors and Market Share
Key Competitors
- Canopy Growth Corp (CGC)
- Tilray Brands Inc (TLRY)
- Organigram Holdings Inc (OGI)
Competitive Landscape
Aurora faces intense competition from larger players with more established brands and greater financial resources. Aurora's advantage lies in its medical focus and international presence. It needs to improve its profitability and market share to compete effectively.
Major Acquisitions
MedReleaf
- Year: 2018
- Acquisition Price (USD millions): 2640
- Strategic Rationale: Expanded Aurora's production capacity and product portfolio, providing access to new markets and technologies.
Growth Trajectory and Initiatives
Historical Growth: Aurora Cannabis Inc. has experienced periods of rapid growth followed by restructuring and consolidation.
Future Projections: Future growth projections are subject to market conditions, regulatory changes, and company performance. Analyst estimates should be consulted for specific forecasts.
Recent Initiatives: Recent initiatives include cost-cutting measures, strategic partnerships, and product innovation.
Summary
Aurora Cannabis Inc. faces financial challenges despite its strategic positioning. The company must improve profitability, reduce debt, and focus on core markets. Though the cannabis market shows promise, Aurora's ability to capitalize depends on effective execution. It should streamline its operations and enhance shareholder value to remain competitive. Navigating regulations and market volatility will be crucial for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions are subject to change. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aurora Cannabis Inc
Exchange NASDAQ | Headquaters Edmonton, AB, Canada | ||
IPO Launch date 2014-07-11 | CEO & Executive Chairman Mr. Miguel Martin | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.auroramj.com |
Full time employees - | Website https://www.auroramj.com | ||
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products. The company also cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, dried flowers, vapes, dried milled strains, edibles, concentrates, and strain specific cannabis oils and extracts; and provides patient counseling and outreach services. Its adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.